Haemonetics (HAE) AI Stock Analysis

• Market Cap: $3.37B
• Dividend Yield: N/A
• Average Volume (3M): 540.13K
• Price to Earnings (P/E): 21.1
• Beta (1Y): 0.84
• Revenue Growth: 3.95%
• EPS Growth: 44.09%
• Country: US
• Employees: 3,657
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.24
• Shares Outstanding: 48,036,995
• 10 Day Avg. Volume: 507,640
• 30 Day Avg. Volume: 540,128
• PEG Ratio: 3.36
• Price to Book (P/B): 6.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 111.81
• Enterprise Value/Market Cap: 1.39
• Enterprise Value/Revenue: 0.86
• Enterprise Value/Gross Profit: 6.26
• Enterprise Value/Ebitda: 4.31
• 1Y Price Target: $90.00
• Price Target Upside: 28.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 76 Outperform
• Price Target: $76.00 ▲(8.43%Upside)

Haemonetics shows strong financial performance with a positive growth trajectory, supported by strategic initiatives and leadership changes. Despite technical resistance and valuation concerns, the company’s guidance and operational strategies contribute positively to its overall outlook.

Positive Factors

Market Share Growth

The outlook looks bright as the company captures material share, benefits from continued pricing gains, and collections improve.

Operational Efficiency

The company delivered a 24.9% adjusted operating margin in the quarter and 24.0% for FY/25, looking to add another 200-300 bps in FY/26.

Revenue and Earnings Performance

Haemonetics generated $330.6 million in revenue, exceeding the consensus estimate of $329.4 million.

Negative Factors

Guidance and Market Expectations

Management provided FY26 revenue and EPS guidance that was below consensus at the midpoints.

Plasma Business Performance

The plasma business declined 9.1% on a reported basis and was down 8.9% organically.

Stock Performance Concerns

The stock has seen a steady decline due to concerns like slowing base plasma collections and the rate of VASCADE XL uptake.

Haemonetics Business Overview & Revenue Model

Company Description

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

How the Company Makes Money

Haemonetics makes money primarily through the sale of its medical devices and software solutions to blood banks, plasma collection centers, and hospitals. The company's revenue streams include the sale of automated blood collection systems, blood processing equipment, and related consumables that are essential for the operation of these devices. Additionally, Haemonetics generates income from software licensing and support services, which provide critical data management and operational efficiencies for its clients. Strategic partnerships and long-term contracts with healthcare providers and organizations further bolster the company's revenue as these collaborations often involve the integration of Haemonetics' technology into large-scale blood management operations.

Haemonetics Financial Statement Overview

Summary

Haemonetics demonstrates strong financial performance with notable revenue growth, improved gross and net profit margins, and effective cost management. The balance sheet shows reduced leverage and a solid equity position, while cash flow is robust with efficient cash management practices.

Income Statement

Haemonetics has demonstrated consistent revenue growth with a notable increase from $993 million in 2022 to $1.36 billion in 2025, reflecting a strong upward trend. The gross profit margin has improved to 55.04%, indicating efficient cost management. The net profit margin has also strengthened to 12.32%, showcasing enhanced profitability. Additionally, the EBIT and EBITDA margins have shown positive growth, contributing to overall financial health.

Balance Sheet

The company's debt-to-equity ratio has improved significantly with a reduction in total debt from $808 million in 2024 to $304 million in 2025, reflecting a stronger equity position. The equity ratio of 33.48% implies a stable financial structure, while the return on equity of 20.42% indicates effective utilization of equity capital. Overall, the balance sheet shows a solid financial position, though there remains room for improving the equity ratio further.

Cash Flow

Haemonetics has experienced positive free cash flow growth with an increase from $115 million in 2024 to $142 million in 2025. The operating cash flow to net income ratio stands at 1.08, indicating effective cash generation relative to profit. The free cash flow to net income ratio of 0.85 supports the company's ability to generate cash after capital expenditures. Overall, the cash flow statement reflects a healthy cash position and efficient cash management practices.

Breakdown
Mar 2025	Mar 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement		Total Revenue
1.36B	1.31B	1.17B	993.20M	870.46M
	Gross Profit
748.96M	691.55M	615.10M	505.50M	397.84M
	EBIT
221.82M	164.88M	156.03M	80.75M	57.96M
	EBITDA
221.82M	265.58M	249.34M	178.50M	142.25M
	Net Income Common Stockholders
167.68M	117.56M	115.40M	43.38M	79.47M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
306.76M	178.80M	284.47M	259.50M	192.31M
	Total Assets
2.45B	2.20B	1.93B	1.86B	1.82B
	Total Debt
303.56M	807.79M	765.89M	773.59M	707.61M
	Net Debt
-3.21M	628.99M	481.42M	514.09M	515.30M
	Total Liabilities
1.63B	1.24B	1.12B	1.11B	1.09B
	Stockholders Equity
820.84M	959.96M	818.00M	749.42M	731.67M
Cash Flow		Free Cash Flow
142.45M	115.45M	162.87M	75.75M	71.77M
	Operating Cash Flow
181.72M	181.75M	273.06M	172.26M	108.81M
	Investing Cash Flow
-161.90M	-322.39M	-143.79M	-86.34M	-425.44M
	Financing Cash Flow
108.82M	38.16M	-100.36M	-15.75M	367.45M

Haemonetics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 70.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAE, the sentiment is Neutral. The current price of 70.09 is above the 20-day moving average (MA) of 69.23, above the 50-day MA of 65.12, and below the 200-day MA of 72.08, indicating a neutral trend. The MACD of 1.51 indicates Negative momentum. The RSI at 57.39 is Neutral, neither overbought nor oversold. The STOCH value of 55.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HAE.

Haemonetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HAE	76 Outperform	$3.37B	21.13	18.83%	―	3.95%	44.09%
ATR	73 Outperform	$9.98B	27.64	15.15%	1.19%	0.34%	17.27%
HOLX	70 Outperform	$14.43B	27.34	11.77%	―	1.66%	21.95%
BDX	68 Neutral	$49.36B	32.86	5.97%	2.42%	5.84%	15.12%
ICUI	68 Neutral	$3.25B	―	-4.62%	―	7.19%	-56.19%
TFX	58 Neutral	$5.30B	37.80	3.48%	1.13%	0.29%	-48.98%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%

Haemonetics Corporate Events

Haemonetics Approves Strategic Alignment Initiative in May 2025

In May 2025, Haemonetics‘ Board of Directors approved a strategic market and regional alignment initiative aimed at enhancing operational performance and reducing costs. This initiative is expected to incur restructuring charges of approximately $20 million, with anticipated annual savings of $30 million upon completion by the end of fiscal 2027. The company reported strong financial results for fiscal 2025, with a 4% increase in annual revenue to $1.361 billion and significant improvements in earnings and cash flow. Despite a decline in fourth-quarter revenue, Haemonetics achieved record margin expansion and operating income growth, driven by its hospital business and strategic pricing initiatives.